Impact on Vulnerable Populations After Discontinuation of Continuous Glucose Monitoring in Patients With Type 2 Diabetes.

Authors

Bernadette Asias-Dinh, Natalie Rosario, Kevin Garey, Aya Hussein, Minoo Madi, Jodie Gee

Published in

The Annals of pharmacotherapy. Pages 10600280261470410. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Continuous glucose monitoring (CGM) reinforces positive nonpharmacologic behaviors and optimizes pharmacotherapy. Long-term CGM may be financially unsustainable in vulnerable populations, but data on durability of benefits after short-term use are limited.
Building upon a prior study of a 3-month pharmacist-led CGM program, this study compared 1-year changes in glycemic management (glycated hemoglobin [A1c]) between patients who continued vs discontinued CGM.
This single-center pilot study, approved by University of Houston Institutional Review Board, was conducted at a federally qualified health center (FQHC). Patients in the initial program continued CGM if they were able to pay for CGM supplies via insurance or self-pay. All patients were followed for 12 months to assess changes in mean A1c and the proportion meeting A1c goals after 3 to 6 (early) and 9 to 12 (late) months.
Fifty-two patients were analyzed (continued CGM: n = 15; discontinued CGM: n = 37). Baseline A1c was similar between the groups. At early follow-up, mean A1c decreased slightly in the continued CGM group (-0.18 ± 1.0; P = .523) but increased significantly in the discontinued group (1.3 ± 1.6; P = .002). At late follow-up, A1c increased nonsignificantly with continued CGM (0.7 ± 1.4; P < .12) but significantly worsened with discontinuation (2.6 ± 1.9; P < .001). The proportion meeting A1c goals also significantly worsened in the discontinuation group.
Although differences existed between groups, this study supports uninterrupted access to CGM for patients with diabetes. Despite initial 3-month use, discontinuation was associated with significant A1c worsening within 1 year. Large-scale, randomized studies are needed to identify whether an optimal timing of personal CGM use exists to sustain glycemic management when consistent use is not feasible.

PMID:
42522272
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.